Teva Pharmaceutical Industries Limited (TEVA) is a leading global pharmaceutical company headquartered in Petach Tikva, Israel, recognized for its comprehensive portfolio that includes both generic and specialty pharmaceuticals, as well as biopharmaceuticals. With a strong foothold in North America and Europe, Teva strategically caters to a diverse range of therapeutic areas, solidifying its position within the competitive pharmaceutical landscape. The company is dedicated to advancing healthcare accessibility through innovative solutions, leveraging its extensive scientific expertise and market presence to improve patient outcomes worldwide. Show more

Location: 124 DVORA HANEVI?A ST., TEL AVIV-YAFO, ISRAEL, 6944020, Tel Aviv-Yafo, 6944020, USA | Website: https://www.tevapharm.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

39.1B

52 Wk Range

$12.47 - $35.69

Previous Close

$34.08

Open

$34.45

Volume

18,625,888

Day Range

$34.14 - $35.69

Enterprise Value

52.7B

Cash

3.556B

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

58.88%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
UZEDY Details Bipolar I Disorder	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SELARSDI™ (ustekinumab-aekn) Details Crohns disease, Ulcerative colitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UZEDY (risperidone) Details Schizophrenia, Mental health	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AUSTEDO® XR (deutetrabenazine) Details Huntington's disease, Dyskinesia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AJOVY® (fremanezumab) Details Pediatric Episodic Migraine Prevention	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TVB-009P (denosumab) (Prolia Biosimilar) Details Osteoporosis	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TEV-‘749 (olanzapine) [Subcutaneous Long-Acting Injectable] Details Schizophrenia	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TEV-’248 (ICS/SABA) Details Asthma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Duvakitug / TEV-’574 (Anti-TL1A) Details Ulcerative colitis, Crohns disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Emrusolmin / TEV-’286 Details Multiple System Atrophy	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TEV-’278 (Anti-PD1-IL2) Details Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TEV-’408 (Anti-IL15) Details Celiac disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TEV-56278 Details Cancer, Melanoma	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.